Active material: gljukozaminilmuramildipeptid
When ATH: L03AX
CCF: Immunostimulatory drug
ICD-10 codes (testimony): A15, B00, B00.5, B02.3, B18.1, B18.2, B97.7, J15, J31, J32, J35.0, J37, J42, L01, L02, L03, L08.0, L40, T79.3
When CSF: 14.01.06
Manufacturer: PEPTEK Company (Russia)
Pills white, round, Valium, chamfered.
| 1 tab. | |
| GMDP (gljukozaminilmuramildipeptid) | 1 mg |
Excipients: lactose, sucrose, potato starch, methyl cellulose, calcium stearate.
10 PC. – упаковки ячейковые контурные (1) – пачки картонные.
10 PC. – упаковки ячейковые контурные (2) – пачки картонные.
Pills white, round, Valium, a facet and Valium.
| 1 tab. | |
| GMDP (gljukozaminilmuramildipeptid) | 10 mg |
Excipients: lactose, sucrose, potato starch, methyl cellulose, calcium stearate.
10 PC. – упаковки ячейковые контурные (1) – пачки картонные.
10 PC. – упаковки ячейковые контурные (2) – пачки картонные.
Immunostimulatory drug, Biological activity is due to the presence endoplasma phagocytes and T-lymphocyte receptors GMDP.
The drug stimulates the functional (baktericidnuю, cytotoxic) activity of phagocytes (neutrophil, macrophages), enhances T cell proliferation- and in- lymphocytes, It increases the synthesis of specific antibodies.
The pharmacological action is carried out by strengthening production of interleukin (Interleukin-1, Interleukin-6, IL-12), Tumor Necrosis Factor, alpha and gamma-interferon, colony stimulating factors.
The drug increases activity of natural killer cells.
Absorption and distribution
Cmax of active substance in plasma achieved through 1.5 h after administration. Oral bioavailability is 7-13%.
The degree of binding to blood albumin weak.
Metabolism and excretion
Active metabolites does not form.
T1/2 is 4.29 no. Excreted unchanged, mostly in the urine.
In the combined therapy of states, accompanied by secondary immunodeficiency, including:
Pills 1 mg 10 mg (for adults)
- Chronic infections of the upper and lower respiratory tract;
- Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (incl. postoperative septic complications);
- With herpes infection (incl. when oftalmogerpese);
- When papillomovirusnoy infection;
- In chronic viral hepatitis B and C;
- Psoriasis (incl. when Arthropathic form);
- Pulmonary tuberculosis.
Pills 1 mg (for children)
- Acute and chronic purulent-inflammatory diseases of the skin and soft tissues;
- Chronic infections of the upper and lower respiratory tract, both in the acute stage, and in remission;
- If any localization of herpes infection;
- In chronic viral hepatitis B and C.
Likopid® administered sublingually or inside an empty stomach, for 30 minutes before eating.
Adults to prevention of postoperative complications Likopid® sublingually administered by 1 mg 1 times / day for 10 days.
To treatment of septic processes of the skin and soft tissues of medium gravity (incl. postoperative) Likopid® sublingually administered by 2 mg 2-3 times / day for 10 days.
To treatment of severe septic processes of the skin and soft tissues Likopid® appointed interior 10 mg 1 times / day for 10 days.
At Chronic infections of the upper and lower respiratory tract Likopid® sublingually administered by 1-2 mg 1 times / day for 10 days.
At pulmonary tuberculosis Likopid® appointed interior 10 mg 1 times / day for 10 days.
At mild form herpes infection Likopid® sublingually administered by 2 mg 1-2 times / day for 6 days; at severe – сублингвально по 10 mg 1-2 times / day for 6 days. At oftalmogerpese Likopid® administered orally at 10 mg 2 times / day for 3 days. After a break 3 day treatment repeat.
At lesions of the cervix with human papillomavirus Likopid® appointed interior 10 mg 1 times / day for 10 days.
To treatment of psoriasis Likopid® administered orally at a dose 10-20 mg 1-2 times / day for 10 days and then every other day 10-20 mg for the next 10 days, at severe and a large area of injury (incl. when Arthropathic form) – внутрь 10 mg 2 times / day for 20 days.
Children aged 1 Year to 16 years Likopid® administered in tablet form 1 mg.
At treating chronic respiratory infections and chronic inflammatory diseases of the skin Likopid® administered orally at a dose 1 mg 1 times / day for 10 days.
At the treatment of herpes infections drug prescribed oral dose 1 mg 3 times / day for 10 days.
At treatment of chronic viral hepatitis B and C – внутрь в дозе 1 mg 3 times / day for 20 days.
Newborns at protracted course of infectious diseases (incl. pneumonia, bronchitis, enterocolitis, sepsis, postoperative complications) Likopid® administered orally at a dose 500 g 2 times / day for 7-10 days.
Maybe: в начале лечения – повышение температуры тела до 37.9°C (is short-lived, It runs independently and does not require discontinuation of the drug).
- Autoimmune thyroiditis in the acute phase;
- Diseases, accompanied by high fever or hyperthermia (>38° C);
- Pregnancy;
- Lactation (breast-feeding);
- Hypersensitivity to the drug.
Use of the drug during pregnancy and lactation (breast-feeding) contraindicated.
It is not appropriate joint appointment Likopid® with sulfanilamidnymi drugs and tetracyclines.
Effects on ability to drive vehicles and management mechanisms
Use of the drug Likopid® It has no effect on the ability to perform work, require increased attention and psychomotor speed reactions.
Currently, cases of drug overdose Likopid® not reported.
In an application Likopid® It increases the effect of antibiotics from the group of semi-synthetic penicillins, cephalosporins, polyene derivatives, fluoroquinolones, marked synergy with antiviral and antifungal agents.
Antacids and adsorbents while the use of Likopid® significantly reduce its bioavailability.
GCS while the application reduce the effectiveness Likopid®.
The drug is released under the prescription.
List B. The drug should be stored in a dry, protected from light, inaccessible to children at temperature not exceeding 25 ° C. Shelf life - 5 years.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More